Drug Patents owned by Ardelyx Inc

1. Drug name - IBSRELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8541448 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Dec, 2029

(7 years from now)

US8969377 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Dec, 2029

(7 years from now)

CN102333759A ARDELYX INC Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Oct, 2014

(7 years ago)

CN103819403A ARDELYX INC Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

CN103819403B ARDELYX INC Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

IN329133B ARDELYX INC Compounds And Methods For Inhibiting Nhemediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

IN201105002P4 ARDELYX INC Compounds And Methods For Inhibiting Sodium Hydrogen Exchanger-Mediated Antiport In Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

EP2384318A2 ARDELYX INC Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

EP3351248A1 ARDELYX INC Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

EP3351248B1 ARDELYX INC Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

EP2384318B1 ARDELYX INC Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408840 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder Dec, 2029

(7 years from now)

US9006281 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders May, 2030

(7 years from now)

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.